Outsourcing Outlook - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing Outlook

Outsourcing No Longer Just for Cost-Cutting

June 2, 2014

Pharmaceutical Technology

With budgets growing, clients see CMOs' costs as less crucial.

Stuck in Neutral

May 2, 2014

Pharmaceutical Technology

The CMO industry's value proposition is limiting its market penetration.

Biopharma Outsourcing Activities Update

April 2, 2014

Pharmaceutical Technology

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Under New Ownership

March 2, 2014

Pharmaceutical Technology

Changes in company ownership shake up the CMO industry.

Novel Expression Systems Opening CMO Opportunities

February 2, 2014

Pharmaceutical Technology

CMOs may find opportunities in alternative expression services.

R&D in Transition

January 2, 2014

Pharmaceutical Technology

The R&D model is in transition and creating new demands on contract services providers.

Climate Change in Outsourcing

December 2, 2013

Pharmaceutical Technology

Ongoing changes create new opportunities for CROs and CMOs.

Disposable Applications in Demand by Biopharma

November 2, 2013

Pharmaceutical Technology

Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

The Expense of Vision in Outsourcing

October 2, 2013

Pharmaceutical Technology

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here